Table 1 Patient demographics and disease characteristics
Patients, n (%) ( N = 470) | |
|---|---|
Median age, y (range) | 65 (30–92) |
Sex | |
Male | 335 (71) |
Female | 135 (29) |
Tumor histology | |
Clear cell | 398 (85) |
Papillary | 25 (5) |
Chromophobe | 5 (1) |
Other | 42 (9) |
ECOG-Performance Status (PS) ≥2 | 60 (13) |
Time to distant metastases (TTBM) | |
Group A (<1 year) | 229 (49) |
Group B (between 1 and 5 years) | 107 (23) |
Group C (>5 years) | 134 (28) |
MSKCC criteria | |
Good | 198 (42) |
Intermediate | 219 (47) |
Poor | 53 (11) |
Median number of bone metastases | 2 |
Median number of SREs (range) | 2 (1–6) |
Sites of concomitant metastases | |
Lung | 276 (59) |
Lymph node | 205 (44) |
Liver | 78 (17) |
Brain | 30 (6) |
Adrenal gland | 14 (3) |
Treatment after onset of bone metastases | 190 (41) |
Sunitinib | 61(12) |
Sorefnib | 4 (1) |
Pazopanib | 24 (5) |
mTor inhibitors | 191 (41) |
Other treatments or no treatemnt |